<DOC>
	<DOCNO>NCT00451763</DOCNO>
	<brief_summary>Idiopathic Macular Telangiectasia characterize incompetent dilate retinal capillary foveolar region unknown cause retinal telangiectasia . In Idiopathic Macular Telangiectasia , proliferative change occur deep retinal capillary network , lead intraretinal neovascularization , unlike age-related macular degeneration , seem retinal rather choroidal origin . Before hemorrhagic fibrotic state , vessel may lead exudation decrease visual acuity . Long-term visual prognosis patient complication may poor treatment laser photocoagulation unproven . Although newly report treatment , photodynamic therapy neovascular membrane associate Idiopathic Macular Telangiectasia , may show vision angiographic stability case , improvement may transient . VEGF implicate major angiogenic stimulus responsible neovascularization AMD , ensue specific anti-VEGF treatment case . The purpose study evaluate intravitreal injection bevacizumab ( 1.25mg/0.05ml ) treatment Idiopathic Macular Telangiectasia .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Idiopathic Macular Telangiectasia</brief_title>
	<detailed_description />
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>patient idiopathic macular telangiectasia patient consent heart attack cerebrovascular attack previous treatment others retinopathy medium opacity preclude visualization fundus inability understand implication protocol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Fovea centralis/pathology</keyword>
	<keyword>Fundus oculus</keyword>
	<keyword>Retinal neovascularization</keyword>
	<keyword>Telangiectasis/diagnosis</keyword>
	<keyword>Tomography , optical coherence</keyword>
	<keyword>Vitreous Body/drug effect</keyword>
</DOC>